Opioid-induced bowel dysfunction

Current Gastroenterology Reports

Volumn 15, Issue 9, 2013, Pages

  Ketwaroo, Gyanprakash A ^a   Cheng, Vivian ^a   Lembo, Anthony ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bowel dysfunction; Constipation; Opioid

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BEVENOPRAN; BISACODYL; FENTANYL; LAXATIVE; LUBIPROSTONE; MACROGOL; MAGNESIUM; METHADONE; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; NALDEMEDINE; NALOXEGOL; NALOXONE; OPIATE; OXYCODONE; PLACEBO; PRUCALOPRIDE; S 297995; TAPENTADOL; TD 1211; UNCLASSIFIED DRUG; NARCOTIC ANALGESIC AGENT;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CHRONIC PAIN; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RELEASE; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; INTESTINE FUNCTION DISORDER; IRRITABLE COLON; LOW BACK PAIN; NAUSEA; OPIOID INDUCED BOWEL DYSFUNCTION; OPIOID INDUCED CONSTIPATION; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TABLET FORMULATION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SUBSTITUTION; GASTROINTESTINAL MOTILITY; REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS;

ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DRUG SUBSTITUTION; GASTROINTESTINAL MOTILITY; HUMANS; LAXATIVES; PRACTICE GUIDELINES AS TOPIC;

EID: 84880665393     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-013-0344-2     Document Type: Article

References (54)

1. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain. 1998;77(3):231-9. (Pubitemid 28451511)
2. Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain. 2001;89(2-3):127-34. (Pubitemid 32146391)
3. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. European journal of pain. 2006;10(4):287-333.
4. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010;152(2):85-92.
5. Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manag. 2007;33(1):67-77. (Pubitemid 46017078)
6. Holzer P. Treatment of opioid-induced gut dysfunction. Expert opinion on investigational drugs. 2007;16(2):181-94. (Pubitemid 46206632)
7. Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis. 2006;24(1-2):105-12.
8. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis research & therapy. 2005;7(5):R1046-1051.
9. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S-8S. (Pubitemid 34072942)
10. • Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society. Apr 2010;22(4):424-430, e496. This survey showed the high prevalence of constipation in patients on chronic opioid therapy.
11. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane database of systematic reviews. 2010(1):CD006605
12. Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain medicine. 2009;10(1):35-42.
13. Pasternak GW. Molecular insights into mu opioid pharmacology: From the clinic to the bench. Clin J Pain. 2010;26 Suppl 10:S3-9.
14. Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain research Molecular brain research Jun. 1997;46(1-2):1-8. (Pubitemid 27214349)
15. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1-3):11-7.
16. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835-42. quiz 843.
17. Finco G, Pintor M, Sanna D, et al. Is target opioid therapy within sight? Minerva Anestesiol. 2012;78(4):462-72.
18. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manag. 2009;37(4):632-41.
19. Radbruch L, Sabatowski R, Loick G, et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliative medicine. 2000;14(2):111-9. (Pubitemid 30198020)
20. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag. 1997;13(5):254-61. (Pubitemid 27240678)
21. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64(3):527-34. (Pubitemid 26180159)
22. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1998;16(4):1588-93. (Pubitemid 28175785)
23. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? European journal of pain. 2010;14(8):781-3.
24. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010;11(11):1787-804.
25. Hersh EV, Golubic S, Moore PA. Analgesic update: tapentadol hydrochloride. Compendium of continuing education in dentistry. Oct 2010;31(8):594-599; quiz 600, 603.
26. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clinical drug investigation. 2010;30(8):489-505.
27. Galvez R, Schafer M, Hans G, Falke D, Steigerwald I. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Adv Ther. 2013;30(3):229-59.
28. Etropolski M, Kelly K, Okamoto A, Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Adv Ther. 2011;28(5):401-17.
29. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63(7):649-71. (Pubitemid 36408072)
30. Herndon CM, Jackson 2nd KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240-50. (Pubitemid 34112884)
31. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Amitiza NDA 021908 Label, April 19, 2013. http://www.accessdata.fda. gov/drugsatfda-docs/label/2013/021908s011lbl.pdf. Accessed May 8, 2013.
32. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Management. 2002;23(1):48-53. (Pubitemid 34093880)
33. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010;64(6):763-74.
34. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative medicine. 2012;26(1):50-60.
35. Foss JF. A review of the potential role of methylnaltrexone in opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):19S-26S. (Pubitemid 34072943)
36. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007;41(6):984-93. (Pubitemid 46917625)
37. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA: the journal of the American Medical Association. 2000;283(3):367-72. (Pubitemid 30051755)
38. • Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-43. This study highlighted the efficacy of one of the most useful therapeutics, subcutaneous methylnaltrexone, in treating opioid-induced constipation without increasing pain or triggering opioid withdrawal. (Pubitemid 351749157)
39. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol Jan-Feb. 2009;7(1):39-46.
40. Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7(2):67-72.
41. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. The journal of pain: official journal of the American Pain Society. 2011;12(5):554-62.
42. Relistor (methylnatrexone) [package insert]. Salix Pharmaceuticals, Inc. Raleigh, NC. 2012.
43. Rauck RL, Peppin JF, Israel RJ, et al. Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain Gastroenterology. 2012;142(5, Supplement 1):S160.
44. Schmidt WK. Alvimopan*(ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182(5A Suppl):27S-38S. (Pubitemid 34072944)
45. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137(2):428-40.
46. Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. The journal of pain: official journal of the American Pain Society. 2011;12(2):185-93.
47. Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. The journal of pain: official journal of the American Pain Society. 2011;12(2):175-84.
48. Astra Zeneca [press release]. AstraZeneca announces positive results from naloxegol pivotal trials in patients with opioid-induced constipation. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/20121211 - astrazeneca-announces-topline. Accessed November 15, 2012.
49. Vickery R, Li Y, Schwertschlag U, Singla N, Webster L, Canafax D. TD-1211 demonstrates improvement in bowel movement frequency and Bristol Stool Scores in a phase IIb study of patients with opioid-induced constipation (OIC). 2012.
50. Techner L, Singla N, Gabriel K, Mangano R. ADL5945, a potent orally bioavailable peripheral opioid receptor antagonist, improves bowel motility w/a low incidence/severity of GI AEs in a dose-dependent manner: results of 2 Ph 2 trials in opioid-induced constipation pts (45CL242 and 45CL243). The Journal of Pain. 2012;13(4, Suppl):S84.
51. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912-21.
52. http://www.shionogi.com/. Accessed May 08, 2013.
53. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Available at: http://www.nccn.org/professionals/ physician-gls/pdf/pain.pdf. Accessed May 08, 2013.
54. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The journal of pain: official journal of the American Pain Society. 2009;10(2):113-30.